Long Term Clinical Outcomes of Angioplasty With Paclitaxel-coated Balloon Only Strategy for Coronary de Novo Lesions: a Single Center Registry Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Coronary Disease
- Sponsor
- Beijing Hospital
- Enrollment
- 300
- Locations
- 1
- Primary Endpoint
- The rate of net adverse cardiac events (NACEs) at 24 months after DCB treatment.
- Last Updated
- 4 years ago
Overview
Brief Summary
Drug-coating balloon (DCB) is a new interventional device for treatment of obstructive coronary artery disease (CAD). There is limited data on the long term efficacy and safety of DCB-only strategy for coronary de novo lesions in Asian patients. We therefore carry out this registry study to evaluated the clinical outcomes of paclitaxel DCB in Chinese patients in a real world medical practice.
Detailed Description
DCB has emerged as a new interventional option to treat obstructive CAD. Characterized by non-stent-based local drug delivery system, DCB has several advantages over drug-eluting stent(DES).Paclitaxel DCB inhibits excessive neointimal hyperplasia of a diseased lesions without leaving a permanent metallic frame, therefore reducing the risk of coronary thrombosis and eliminating adverse events associated with stent fracture, allergic reactions to metal struts or polymer. Since only 1 to 3 months duration of dual anti-platelet therapy(DAPT) is required after DCB intervention, the bleeding risk associated with prolonged DAPT is reduced. DCB angioplasty was proved safe in an all-comers, prospective, multicenter registry and confirmed not inferior to DES when treating small coronary lesions in a randomized clinical trial(BASKET SMALL-2). DCB has been used in"off-label"indications in the"real world" for de novo lesions, especially in vessels with diameter more than 2.75mm, and there is limited data on its long term clinical efficacy and safety in Asian patients in contemporary clinical registries. We therefore sought to evaluate the long term clinical outcome of DCB in treatment of coronary de novo lesions in Chinese patients.
Investigators
Xue Yu
Vice Director of Cardiology Department
Beijing Hospital
Eligibility Criteria
Inclusion Criteria
- •Patient-related criteria：
- •Patients with stable angina, unstable angina, myocardial infarction or evidence of asymptomatic myocardial ischemia and consent to receive coronary intervention therapy;
- •Consent to receive clinical follow up at 30 days, 3, 6, 12 and 24 months.
- •Consent to receive one angiographic follow up at 24 months after procedure.
- •Lesion-related criteria：
- •Target coronary lesions without previous intervention therapy;
- •The lesions was intervened only with DCB;
- •The distance between other lesions requiring intervention therapy and the target lesion must \>10mm.
Exclusion Criteria
- •Patient-related criteria：
- •Severe congestive heart failure\[LVEF \<30% or NYHA( New York Heart Association) III/IV)\]
- •Severe valvular heart disease;
- •Pregnant or breastfeeding women;
- •Life expectancy no more than 1 year or factors causing difficulties in clinical follow up;
- •Bleeding predisposition, contraindications of anticoagulants or antiplatelet agents;
- •Intorerance to aspirin and/or clopidogrel or other anti platelet drugs;
- •Leukopenia or thrombopenia;
- •Stroke within 6 months prior to the operation;
- •A history of severe hepatic or renal failure.
Outcomes
Primary Outcomes
The rate of net adverse cardiac events (NACEs) at 24 months after DCB treatment.
Time Frame: Clinical follow-up at 24 months after the procedure.
A composite endpoint of NACEs, including cardiovascular death, myocardial infarction, target lesion revascularization, target vessel revascularization, stroke, all cause bleeding.
Secondary Outcomes
- Late lumen loss(LLL) at 24 months follow-up(Coronary angiography follow-up at 24 months after the procedure.)